Under this collaboration, Harvard Medical School (ICCB-L) will utilize the CellaxessHT system, a high throughput transfection enabling reagent-free delivery system, for genome-wide RNAi delivery to biologically relevant cell types.
Jonas Ohlsson, CEO of Cellectricon, said: “Cellectricon is extremely proud to collaborate with a research institution such as Harvard Medical School. We look forward to jointly advance the RNAi research area by our technology, as we’re confident that CellaxessHT will aid in the generation of more relevant results from RNAi screening campaigns.”